Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 206 clinical trials
featured
A Phase III study of the Efficacy and Safety of subjects with Moderately to Severe active Rheumatoid Arthritis which have been inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) inhibitor therapy

A Phase III study of the Efficacy and Safety of subjects with Moderately to Severe active Rheumatoid Arthritis which have been inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) inhibitor

  • 302 views
  • 25 Mar, 2021
  • 1 location
featured
A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.

A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.

  • 180 views
  • 25 Mar, 2021
  • 1 location
featured
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

  • 2362 views
  • 23 Nov, 2020
  • 18 locations
Genetic Polymorphisms of TNF- Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease

contribute to disease severity. Cytokine gene polymorphism has been regarded affecting prognosis of disease. By detecting HBV genotyping and tumor necrosis factor-alpha polymorphism, this study

hepatocellular carcinoma
tumor necrosis factor-alpha
cirrhosis
liver disease
tumor necrosis factor
  • 0 views
  • 07 Nov, 2020
  • 1 location
Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC)

Soluble Tumor Necrosis Factor Receptors (sTNF-Rs) from plasma of patients with advanced, refractory Triple Negative Breast Cancer (TNBC) and for disease control when employed as monotherapy, or in

  • 30 views
  • 27 Jan, 2021
  • 6 locations
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases

phototherapy
adalimumab
tumor necrosis factor
tumor necrosis factor alpha
  • 1 views
  • 07 Nov, 2020
  • 1 location
Can a Modified Fat Diet With Low Glycaemic Load Improve Insulin Sensitivity and Inflammatory Mediators in Overweight People With Chronic Heart Failure?

distance and Heart Failure Quality of Life [HF QOL] Questionnaire) - body weight - inflammatory mediators (tumor necrosis factor [TNF] alpha, C-reactive protein [CRP

chronic heart failure
  • 16 views
  • 07 Nov, 2020
  • 1 location
Evaluation of PET CT in the Management of Patients With Crohn's Disease.

this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the

inflammatory bowel disease
tumour necrosis
remission
tumor necrosis factor
tumor necrosis factor alpha
  • 15 views
  • 07 Nov, 2020
  • 1 location
Topical Infliximab for Sterile Corneal Melt

necrolysis or mucous membrane pemphigoid. Infliximab is an antibody against tumour necrosis factor alpha and has been used to treat or prevent corneal melt in certain patients with inflammatory of

  • 3 views
  • 03 Feb, 2021
  • 2 locations
Adjunctive Sedation With Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy

a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators such as tumor necrosis factor (TNF)-, Interleukin (IL)-1 and IL-6

  • 0 views
  • 07 May, 2021
  • 1 location